Atea Pharmaceuticals (AVIR) Operating Income (2020 - 2022)
Historic Operating Income for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to -$39.9 million.
- Atea Pharmaceuticals' Operating Income fell 13292.51% to -$39.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$130.6 million, marking a year-over-year decrease of 19441.67%. This contributed to the annual value of -$193.0 million for FY2024, which is 1753.63% down from last year.
- As of Q4 2022, Atea Pharmaceuticals' Operating Income stood at -$39.9 million, which was down 13292.51% from -$16.3 million recorded in Q3 2022.
- Atea Pharmaceuticals' Operating Income's 5-year high stood at $121.2 million during Q4 2021, with a 5-year trough of -$42.2 million in Q1 2022.
- Moreover, its 3-year median value for Operating Income was -$16.3 million (2022), whereas its average is $67363.6.
- Its Operating Income has fluctuated over the past 5 years, first soared by 48691.82% in 2021, then crashed by 47176.24% in 2022.
- Atea Pharmaceuticals' Operating Income (Quarter) stood at $20.6 million in 2020, then soared by 486.92% to $121.2 million in 2021, then crashed by 132.93% to -$39.9 million in 2022.
- Its Operating Income stands at -$39.9 million for Q4 2022, versus -$16.3 million for Q3 2022 and -$32.3 million for Q2 2022.